Galapagos to wind down cell therapy business after failed attempt at sale

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: After months of back-and-forth announcements, Galapagos now plans to wind down its cell therapy business and focus resources on building a pipeline of new medicines through deals and acquisitions. If this plan happens, the Belgian biotechnology company expects to lay off about 365 workers, or more than half of the 704-person workforce it employed ...